Marathon Asset Management 13F: Cuts CME Stake by $2M
Key Points
- Marathon Asset Management now holds 87,498 shares of CME Group, valued at about $22.9 million after the reduction.
- The fund's position in CME Group accounts for 1.82% of its total reported value of approximately $1.26 billion.
- CME Group recently traded around $305.71, slightly below its closing price of $308.06 on the filing date.
Get CME Group text alerts
We text you when insiders, Congress, analysts or big funds move on $CME.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated CME Group Inc. alert may contain errors. Disclosures
Marathon Asset Management trimmed its stake in CME Group Inc. (CME) by 7,675 shares in a filing on October 26, 2026.
CME
CME Group Inc.
Where CME Fits in Marathon Asset Management's Portfolio
This position represents 1.82% of Marathon's total reported value of about $1.26 billion, ranking it 21st among the fund's 76 holdings.
Other Institutional Activity in CME Group
RMR Wealth Builders grew its holdings by 2,415 shares, ending with 20,190 shares worth about $5.3 million. Meanwhile, Carnegie Investment Counsel reduced its stake by 7,393 shares, now holding 152,288 shares valued at approximately $37.9 million. Y-Intercept saw a significant drop, selling 95,086 shares, leaving it with 53,259 shares valued at around $13.9 million.
CME Group Inc. Stock Down 0.1%
CME Group shares closed at $308.06 on October 26, 2026, and recently traded around $305.71, which is slightly below the event-day close. This indicates a minor decline of about 0.8% since the filing date.
Recent Earnings
CME Group reported trailing twelve-month revenue of approximately $6.96 billion, with a net margin of 63.5% and return on equity of 16.1%. The next earnings report is scheduled for February 3, 2027.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 0 raises.
-
EPS & revenue
EPS missed estimates by 1.2%. Revenue missed estimates by 1.6%.
-
Profit surprise
EBITDA missed by 6 percent. Operating income missed by 5 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
2 target cuts.
-
Earnings quality
Gross margin up 0.7 points. Operating margin up 2.2 points. Positive free cash flow.
Earnings Call Summary
CME delivered a record first quarter with average daily volume of 36.2 million contracts, up 22 percent year-over-year, marking the highest in company history. Revenue reached $1.88 billion, up 14 percent, with record performance across all six asset classes and international markets. The company achieved record adjusted operating margins of 72.8 percent and adjusted earnings per share of $3.36, returning $3.2 billion to shareholders through dividends and buybacks.
Guidance CME reaffirmed its full-year adjusted expense guidance of about $1.695 billion. The company expects to continue investing in technology and cloud migration while maintaining capital returns through dividends and share buybacks.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
CME Group pays an annual dividend of $5.20 per share, with a payout ratio of 95.4%.
Insider Buying and Selling at CME Group Inc.
On September 10, 2026, CEO Terrence A. Duffy sold 15,000 shares valued at about $4.12 million. Director Elizabeth A. Cook sold 500 shares for $140,055 on September 14, 2026. Director William R. Shepard bought 292 shares at an average price of $268.76 on September 25, 2026. Additionally, Director Martin J. Gepsman sold 400 shares on October 22, 2026, valued at $121,000.
Analysts Set New Price Targets
On October 22, 2026, multiple firms maintained their ratings on CME Group, with UBS holding a "Neutral" rating and a target of $310, while Morgan Stanley maintained an "Overweight" rating with a target of $359. Barclays and Wells Fargo also kept their ratings, with targets of $321 and $333, respectively.
About CME Group
CME Group Inc. operates markets for trading futures and options on various financial products worldwide, including interest rates and commodities. The firm plays a crucial role in the financial services sector, providing essential trading services.
Bottom Line
Marathon Asset Management's recent trim of its CME stake may reflect a strategic adjustment in its portfolio. Investors should keep an eye on CME's upcoming earnings report on February 3, 2027, and any further changes in institutional holdings.
Related Filing Alerts
Source: Marathon Asset Management's 13F filing on $CME (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts